Pliant Therapeutics, Inc. Stock Price, News & Analysis

Pliant Therapeutics (Nasdaq: PLRX) reported Phase 1 data for lead oncology candidate PLN-101095 showing deep, durable responses in ICI‑refractory solid tumors and announced an accelerated development plan with a Phase 1b indication expansion trial.

Key items: four responders in 10 secondary ICI‑refractory patients, initiation of NSCLC/clear cell RCC/high‑TMB cohorts with enrollment expected Q2 2026 and interim data in 2027, published INTEGRIS‑PSC results, new COO appointment, and $192.4M cash runway into H2 2028.

Pliant Therapeutics (Nasdaq: PLRX) will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual format on February 25-26, 2026. A fireside chat featuring Bernard Coulie, M.D., Ph.D., CEO, and Keith Cummings, M.D., CFO, is scheduled for Feb 25, 2026 at 2:40 p.m. ET.

According to the company, the live webcast will be accessible via Pliant’s Investor Relations events page, and a replay will be archived on the Pliant website for 30 days after the event.

Pliant Therapeutics (NASDAQ: PLRX) reported interim Phase 1 dose-escalation data for oral PLN-101095 combined with pembrolizumab in ICI-refractory advanced/metastatic solid tumors dated Dec 4, 2025. In the three highest dose cohorts, 4 responders were observed among 10 secondary ICI-refractory patients (1 confirmed CR, 2 confirmed PR, 1 unconfirmed PR). Median time on treatment for responders was 15 months as of Nov 30, 2025. 60% of secondary refractory patients showed stable disease or tumor reduction. Responders had 4- to 13-fold increases in plasma IFN-γ after 14-day PLN-101095 monotherapy. Drug was generally well tolerated with 2 discontinuations. Company plans a Phase 1b expansion in 2026 and says cash supports operations through 2028.

Pliant Therapeutics (Nasdaq: PLRX) will participate in the Piper Sandler 37th Annual Healthcare Conference, December 2–4, 2025. A fireside chat featuring Bernard Coulie, M.D., Ph.D. (CEO), Keith Cummings, M.D. (CFO) and Éric Lefebvre, M.D. (CMO) is scheduled for Thursday, December 4, 2025 at 12:30 p.m. ET.

Interested parties can access a live webcast via the company’s Investor Relations Events & Presentation page. A replay will be archived on the Pliant website for 90 days after the event.

Pliant Therapeutics (Nasdaq: PLRX) provided a corporate update and reported third quarter 2025 results on Nov 6, 2025. The company completed enrollment in the Phase 1 open-label trial of PLN-101095 in solid tumors; interim data showed a 50% objective response rate in one dose cohort and full trial data, including the two highest dose cohorts, are expected by the end of 2025. Close out activities for the BEACON‑IPF Phase 2b/3 trial are expected to finish in Q4 2025, with full results planned for future publication. In October the company completed a voluntary prepayment of its March 11, 2024 loan with Oxford Finance. Q3 2025 results: R&D $17.9M (prior $47.8M), G&A $10.3M (prior $14.3M), Net loss $26.3M (prior $57.8M), and Cash & short-term investments $243.3M as of Sept 30, 2025.

Pliant Therapeutics (NASDAQ:PLRX) reported Q2 2025 financial results and provided significant updates on its clinical programs. The company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF) due to an unfavorable risk-benefit profile, despite early efficacy signs. Their Phase 1 oncology trial for PLN-101095 continues to progress, with data expected by year-end 2025.

Financial highlights include a reduced net loss of $43.3 million compared to $55.9 million in the prior year quarter. The company ended Q2 with $264.4 million in cash and equivalents. A strategic workforce restructuring was largely completed in Q2 2025, resulting in decreased R&D expenses of $32.2 million (down from $45.6 million) and reduced G&A expenses of $13.4 million (down from $15.0 million).

Pliant Therapeutics (NASDAQ:PLRX) announced the discontinuation of bexotegrast development for idiopathic pulmonary fibrosis (IPF) following unfavorable results from the BEACON-IPF Phase 2b/3 trial. The trial was terminated due to an imbalance in IPF-related adverse events, with bexotegrast-treated participants showing increased risk of disease progression.

Despite initial improvements in forced vital capacity (FVC) at Week 12, the drug demonstrated an unfavorable risk-benefit profile at both 160mg and 320mg doses. The company continues to advance its clinical oncology program, with PLN-101095 showing promising interim results in Phase 1 trials, including 50% partial response rates in the highest dose cohort.

Pliant Therapeutics (PLRX) presented clinical and preclinical data at the American Thoracic Society 2025 International Conference, highlighting three key studies on their drug bexotegrast. The first study showed that bexotegrast, a dual inhibitor of αVβ6/αVβ1 integrins, reduced fibrosis-related gene expression in lung cells from non-IPF ILD patients. A second study identified biomarkers across different ILD subtypes that could help inform clinical decisions. The third study demonstrated bexotegrast's distinct antifibrotic effects, showing superior results compared to nintedanib in reducing profibrotic genes in specific cell types, both alone and in combination therapy.

Pliant Therapeutics (NASDAQ: PLRX) reported Q1 2025 financial results and provided corporate updates. The company is finalizing its BEACON-IPF Phase 2b/3 trial with topline data expected in Q2 2025. Their oncology program showed promising results, with PLN-101095 demonstrating antitumor activity in combination with pembrolizumab, achieving confirmed partial responses in 3 out of 6 patients at the highest dose tested. The company announced a strategic realignment including a 45% workforce reduction to extend cash runway. Financial results showed R&D expenses of $43.4M (up from $37.1M YoY), G&A expenses of $15.5M, and a net loss of $56.2M (compared to $47.0M YoY). As of March 31, 2025, Pliant maintained a strong cash position of $307.1M in cash, cash equivalents, and short-term investments.